Answers are grounded in this paper and cite their sources.
Background: Depression epidemic is likely to follow the COVID pandemic. Depression is treatable if compliance is good. The study was aimed at identifying risk factors of poor antidepressant compliance during a pandemic. Materials and Methods: Sixty-four poor compliers of antidepressants during COVID period were compared with equal number of poor compliers of pre-COVID period on sociodemographic and clinical characteristics. The retrospective study was designed in a way to eliminate biases due to usual patient, social, or clinical factors. The hypothesis was that there would be some factors of antidepressant poor compliance exclusive to pandemic and these factors would be beyond the usual factors. Results: Majority ( n = 43, 67%) of COVID period poor compliers were family members of employees. Subjects who came for prescription refill ( n = 17, 27%) than consultation were poor compliant during COVID period. COVID period poor compliers ( n = 6, 9%) were admitted less compared to pre-COVID counterparts ( n = 15, 23%). COVID period subjects had mood symptoms predominant depression ( n = 44, 69%) than physical symptoms ( n = 20, 31%). The presence of death wish or suicidal ideas was significant ( n = 16, 25%) in COVID period. Poor compliers of pandemic ( n = 26, 41%) had more psychosocial stress ( P < 0.05). Conclusion: The study did find some exclusive factors apart from doctor–patient relationship for good compliance. Depressive patients who perceive improvement in mood symptoms are poor compliers during pandemic. Compliance improves if patients find some primary purpose to come out during pandemic. Ongoing stress also reduces compliance.
No takes yet. Share an insight, caveat, or question.
Suhash Chakraborty (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: